Balancing Survival Benefits, Toxicity, and Guideline Recommendations

This episode explores how overall survival data, toxicity profiles, and guideline categorizations inform frontline decision-making. Combination regimens are discussed as delivering meaningful overall survival extensions compared with osimertinib monotherapy, with particularly important benefits in CNS control. At the same time, these strategies introduce added toxicity that must be weighed against each patient's goals and comorbidities. The role of NCCN "category 1 preferred" status is examined: useful as a signal of robust evidence and for payer coverage, but not always the decisive factor when biologic rationale and emerging data support alternate approaches. The segment then pivots to brain metastases as a defining issue in EGFR-mutant NSCLC, including the concept of using CNS-active targeted therapies to defer or avoid upfront radiation. Prospective serial brain MRI data from MARIPOSA are highlighted as increasing confidence in intracranial efficacy for combination regimens.